William Blair analyst Brandon Vazquez has maintained their bullish stance on XRAY stock, giving a Buy rating on February 11.
Brandon Vazquez has given his Buy rating due to a combination of factors influencing DENTSPLY SIRONA’s future outlook. Despite a challenging fourth quarter where sales and earnings per share fell short of expectations, the company is expected to overcome these hurdles by 2025. The realignment of Byte clear aligners, which had a significant negative impact on revenues, is anticipated to stabilize, contributing to a more favorable financial performance in the future.
Additionally, the company’s shares are currently valued at a discount compared to its peers, trading at 10 times the projected 2025 earnings per share. This presents a potential opportunity for growth, especially with the company’s ongoing efforts in digital adoption, which is seen as a crucial factor for long-term success in the dental industry. These elements combined support the Buy rating, reflecting optimism for the company’s strategic initiatives and market positioning.
In another report released on February 11, Needham also reiterated a Buy rating on the stock with a $25.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com